HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group

J&J gets EMA nod for wider use of Erleada in prostate cancer

So far, Erleada – which was also approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) a few months ahead of Xtandi and Bayer’s recently-approved competitor  Nubeqa (darolutamide) – ... This week, Bayer reported updated

Roche files Tecentriq/Avastin combo in liver cancer

Patients received PD-L1 inhibitor Tecentriq plus anti-VEGF antibody Avastin or Bayer’s Nexavar (sorafenib) – a standard first-line therapy for HCC.

Immuno-oncology, personalised medicine continues to drive pharma sector

A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was ... discussion with Bayer for access to the drug.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]